Search for Clinical Trial Results

Hemolysis - 25 Studies Found
Status | Study |
Recruiting |
Study Name: Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty Condition: Hemolysis Date: 2008-11-17 Interventions: Drug: Propofol Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) |
Completed |
Study Name: Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling Condition: Hemolysis Date: 2015-11-24 Interventions:
|
Recruiting |
Study Name: Clinical Study of a Novel Hemolysis Point of Care Test at an Emergency Department. Condition:
Date: 2016-11-24 Interventions: Device: Hemolysis Point-of-Care test Hemolysis measurement of plasma using a point of care test to deter |
Completed |
Study Name: Isoagglutinins in the Development of IVIG-associated Hemolysis Condition:
Date: 2014-08-29 |
Completed |
Study Name: Hemolysis in Patients With Hereditary Spherocytosis (HS) Condition:
Date: 2010-09-12 Interventions: Other: fermented papaya preparation (FPP) Hemolysis will be assayed by suspending 3 ml of packed RBC in |
Not yet recruiting |
Study Name: Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease Condition: Haemolysis Neonatal Date: 2017-04-24 Interventions: Drug: intravenous immunoglobulin giving intravenous immunoglobulin to neonates included in inclusion cri |
Completed |
Study Name: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient |
Recruiting |
Study Name: A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) Condition: Warm Antibody Autoimmune Hemolytic Anemia Date: 2015-11-19 Interventions: Drug: Fostamatinib 150 mg bid Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any ti |
Recruiting |
Study Name: R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions Condition: Hemolysis Date: 2012-03-16 |